Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research

Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of...

Descripción completa

Detalles Bibliográficos
Autores principales: Khansur, Emaad M, Shah, Ashish H, Lacy, Kyle, Kuchakulla, Manish, Komotar, Ricardo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Neurosurgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910011/
https://www.ncbi.nlm.nih.gov/pubmed/29692957
http://dx.doi.org/10.7759/cureus.2130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910011/
https://www.ncbi.nlm.nih.gov/pubmed/29692957
http://dx.doi.org/10.7759/cureus.2130

Ejemplares similares